Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2–4 and 10

被引：0
|
作者：
Matthew Capehorn
Yasmin Ghani
Charlotte Hindsberger
Pierre Johansen
Esteban Jódar
机构：
[1] Rotherham Institute for Obesity (RIO),
[2] Clifton Medical Centre,undefined
[3] Novo Nordisk A/S,undefined
[4] S-cubed APS (contracted by Novo Nordisk A/S),undefined
[5] Novo Nordisk A/S,undefined
[6] Hospital Universitario Quiron Salud Madrid,undefined
[7] Universidad Europea de Madrid,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
Diabetes care; GLP-1RA; Metformin; Oral antidiabetic agents; Randomised controlled trials; Semaglutide; Sulphonylurea; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1061 / 1075
页数：14
相关论文
共 50 条
  • [1] Once-Weekly Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Common OAD: a Subgroup Analysis from SUSTAIN 2-4 and 10
    Capehorn, Matthew
    Ghani, Yasmin
    Hindsberger, Charlotte
    Johansen, Pierre
    Jodar, Esteban
    DIABETES THERAPY, 2020, 11 (05) : 1061 - 1075
  • [2] Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
    Pratley, Richard E.
    Crowley, Matthew J.
    Gislum, Mette
    Hertz, Christin L.
    Jensen, Thomas B.
    Khunti, Kamlesh
    Mosenzon, Ofri
    Buse, John B.
    DIABETES THERAPY, 2021, 12 (04) : 1099 - 1116
  • [3] Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
    Richard E. Pratley
    Matthew J. Crowley
    Mette Gislum
    Christin L. Hertz
    Thomas B. Jensen
    Kamlesh Khunti
    Ofri Mosenzon
    John B. Buse
    Diabetes Therapy, 2021, 12 : 1099 - 1116
  • [4] The once-weekly human GLP-1 analogue semaglutide provides significant reductions in HbA1c and body weight in patients with type 2 diabetes
    Nauck, M. A.
    Petrie, J. R.
    Sesti, G.
    Mannucci, E.
    Courreges, J-P
    Atkin, S.
    Duering, M.
    Jensen, C. B.
    Heller, S.
    DIABETOLOGIA, 2012, 55 : S7 - S7
  • [5] Semaglutide reduces HbA1c and body weight across multiple background OAD treatment categories
    Capehorn, M.
    Frias, J.
    Tabak, O.
    Tadayon, S.
    Zacho, J.
    Aroda, V. R.
    DIABETOLOGIA, 2017, 60 : S374 - S375
  • [6] Effect of once-weekly semaglutide 2 mg vs 1 mg on HbA1c and body weight by baseline demographic subgroups: SUSTAIN FORTE post hoc analysis
    Frias, J. P.
    Bardtrum, L.
    Hansen, Y.
    Lingvay, I.
    Macura, S.
    Tentolouris, N.
    Buse, J. B.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S289 - S290
  • [7] Influence on HbA1c and weight by baseline body mass index with once-weekly dulaglutide in Chinese patients with type 2 diabetes mellitus
    Shi, Yongquan
    Zhang, Bin
    Wu, Haiya
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [8] Impact of Once-Weekly Semaglutide on eGFR and Hemoglobin A1c (HbA1c) among Patients with Type 2 Diabetes and CKD: An Observational Study
    Amamoo, James J.
    Sheth, Sunny T.
    Brady, Brenna L.
    Tran, Anh Thu
    Xie Lin
    Noone, Josh
    Mehanna, Sherif
    Bakris, George L.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [9] Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials
    Jendle, Johan
    Birkenfeld, Andreas L.
    Polonsky, William H.
    Silver, Robert
    Uusinarkaus, Kari
    Hansen, Thomas
    Hakan-Bloch, Jonas
    Tadayon, Sayeh
    Davies, Melanie J.
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2315 - 2326
  • [10] Canagliflozin reduces both HbA1c and body weight in patients with type 2 diabetes mellitus on background metformin
    Langslet, G.
    Davidson, J. A.
    Valentine, V.
    Vijapurkar, U.
    Canovatchel, W.
    Meininger, G.
    DIABETOLOGIA, 2014, 57 : S348 - S348
12345